Αdverse effects of chemotherapy and radiotherapy

Similar documents
Long term toxicity of treatment. Laurence Brugieres Children and Adolescent Oncologic department

PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP. Denise Rokitka, MD, MPH

Medical Late Effects of Childhood Cancer

Prevention and screening of long term side effects. Lena Specht MD DMSc Professor of Oncology Rigshospitalet, University of Copenhagen Denmark

Late effects, health status and quality of life after hemopoietic stem cell

Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα

Late Effects in Pediatric Cancer Survivors

Disclosures. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.

Chemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY

Cardiotoxicity: The View of the Cardiologist

SURVIVORSHIP WITH LYMPHOMA APRIL SHAMY MD,CM JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY

CARDIOVASCULAR TOXICITY INDUCED BY ANTITUMOUR THERAPY. Florian SCOTTE, MDPhD Suresnes, France

Chronic Disease Working Group CCSS Investigator Meeting 2015

Breast Cancer and the Heart

Managing LV Impairment with Cancer Therapies

Cardiovascular outcomes in survivors of childhood cancer

Disturbances of female reproductive system in survivors of childhood cancer

Cancer and the heart: New evidence and open issues

Combined drug and ionizing radiation: biological basis. Prof. Vincent GREGOIRE Université Catholique de Louvain, Cliniques Universitaires St-Luc

Cardiotoxicities of Cancer in Childhood Cancer Survivors

Cancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center

Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension Arrhythmias Miscellaneous ( pericardial inflammation, valvular abnormalities )

CARDIOTOXICITY IN ONCOLOGY PRACTICE

Cardio-oncology: Applying new echo technology to guide therapy

Τhe unique constellation of tumors in AYA: Not an adult, not a child

AYA & XYZ: Care of the Childhood Cancer Survivor & Adolescent/Young Adult Oncology

Late complications after hematopoietic stem cell transplant in adult patients

ISCHEMIC HEART DISEASE IN THE CANCER PATIENT: THOMAS M. SUTER MD UNIVERSITY HOSPITAL BERN, SWITZERLAND

Why? What? When? How? Dr C Fryer FRCPC) Surveillance

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.

Survivorship: Managing Cardiac Toxicities

MASCC Guidelines for Antiemetic control: An update

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

5 (Mullan F. N Engl J Med 313(4):270-3)

Second Neoplasms Working Group. CCSS Investigators Meeting June 2017

Female Health Issues after Treatment for Childhood Cancer

Physical Issues Cancer Survivors Face and Interventions for Improved Physical Well-Being

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

Cancer Prevention & Control in Adolescent & Young Adult Survivors

CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long

Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity

The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors

Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer

Cardiac Toxicities Associated with Cancer Treatment

Surviving Breast Cancer

THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)

MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials?


Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI

The Current Pediatric Oncology Landscape

How to Evaluate the Heart of Elderly Patients

Cardio oncology Double Jeopardy

17 th Annual Benjamin Schuster, MD Colloquium February 22 nd, 2017:

Late Effects of Treatment on the Heart. Jennifer H. Jordan, PhD, MS William O. Ntim, MD, FACC, FACP

Chemo-radiation and targeted agents: biological basis

Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy

When do you delay surgery?

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

Clinical Perspective: How Are We Doing From a Clinician s Point of View

DRUG EXTRAVASATION. Vesicants. Irritants

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

Guidelines for the Use of Anti-Emetics with Chemotherapy

It s not just the chemo a case of exertional dyspnoea in a Hodgkin survivor.

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

Cancer in adolescents and Young Adults

Predicting the risk of late effects among cancer survivors: moving toward risk-stratified care

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

Supplementary Appendix

Emily S. Tonorezos, MD MPH Adult Long-Term Follow-Up Program

1. Study Title. Exercise and Late Mortality in 5-Year Survivors of Childhood Cancer: a Report from the Childhood Cancer Survivor Study.

Endocrine Late Effects in Survivors of Pediatric SCT

Lipoplatin monotherapy for oncologists

CHEMOTHERAPY. Chemo, Ctx, Ctx. A category of cancer treatment that uses one or more anti-cancer drugs. Risk factor Male & Female

Clinical Tools and Resources for Self-Study and Patient Education

Radiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2

Original Article Left Ventricular Ejection in Cancer Patients Pak Armed Forces Med J 2014; 64 (3):468-72

CHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in Survivors of Childhood Leukemia with Down Syndrome Analysis Concept Proposal

Cancer: recent advances and implications for underwriting

Cardio-Oncology at MHI. Kasia Hryniewicz, M.D.

Why do patients take herbs and nutritional supplements?

What s a Transplant? What s not?

Hormone Deficiencies in Cancer Survivors MEMS Annual Congress (MAC) May 2013

Pulmonary Complications of Cancer Treatment

Cardiovascular Risk in Patients Undergoing Bone Marrow Transplant: How to Assess? Saro Armenian, DO, MPH Joerg Hermann, MD

Anti-cancer drugs. Introduction : Body : 1) Alkylating Agents

Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus

Non-Anthracycline Adjuvant Therapy: When to Use?

Table 1: Preparatory tests for LTX.

Childhood Cancer Survivor Study Analysis Concept Proposal

NCCP Chemotherapy Protocol. INDICATION ICD10 Protocol Code Hodgkin s Lymphoma C a

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors

The Road to Improve Cardiovascular Health after Cancer. S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018

Cardio-Oncology: Cardiac care specific to cancer patients and survivors. Learning Objectives

The role of liposomal doxorubicin in DLBCL lymphomas. Michele Spina Aviano

Member, St. Jude Children s Research Hospital (senior author)

Emetogenicity level 1. Emetogenicity level 2

Cardio-Oncology: Past Present and Future

CURATIVE THERAPY FOR PEDIatric

Transcription:

Αdverse effects of chemotherapy and radiotherapy Giannis Mountzios MSc, PhD Medical Oncologist 251 General Aiforce Hospital 2 nd Oncology Department, Henry Dunant Hospital Centre Athens, Greece ESMO Preceptorship on Adolescents and Young adults with cancer Saturday 12 May 2018

Αdverse effects of treatment in AYA Defined as the effects of antineoplastic treatment (chemotherapy and radiotherapy) occurring during and after completion of treatment. A huge emerging issue as approximately three quarters of adolescents achieve long-term survival. Caused by the cancer, and the delivery of intense multimodality treatment to AYA. They can affect every aspect of patient s health, quality of life and psychological well being. Woodward et al 2011 25/05/2018 2

Adverse effects by Surgery Disabling surgery is a cause of late effects interfering with patient s quality of life. Mutilating surgery in the limbs, head and neck or torso causes disfigurement with resultant functional disabilities This may not always be necessary, such as limb-sparing surgery with modern endoprostheses has enabled preservation of functional limbs Hollis R et al. Lancet Oncology 2001 25/05/2018 3

Effects of Chemotherapy 25/05/2018 4 Pentheroudakis G and Pavlidis N Cancer Treat Rev 2007

Effects of Chemo: Alkylating agents and heavy metals Mechlorethamine, melphalan, nitrosoureas, busulfan, chlorambucil Cyclophosphamide, ifosfamide, platinum analogs Mutagenic and carcinogenic (secondary AML) Associated with infertility (amenorrhea, azoospermia) Lung injury (High dose busulphan) Renal injury (with acquired Fanconi s syndrome) Neurotoxicity, ototoxicity ( irreversible if not diagnosed early) 5 Pentheroudakis G and Pavlidis N Cancer Treat Rev 2007

Effects of chemo: Anthracyclines Adriamycin, epirubicin, daunorubicin, idarubicin Late cardiotoxicity (free-radical damage of cellular nucleic acids, lipids and proteins): Myocardial cell injury Increased afterload Left ventricular systolic dysfunction Congestive heart failure The cumulative anthracycline dose seems to be the most important determinant of the incidence of cardiotoxicity Increased risk by chest irradiation, smoking, 25/05/2018 6 hypertension, diabetes, dyslipidemia, cardiotoxic agents

Effects of chemo: cardiomyopathy 25/05/2018 7 Pentheroudakis G and Pavlidis N Cancer Treat Rev 2007

25/05/2018 8 Long Pentheroudakis G and Pavlidis N Cancer Treat Rev 2007 term

Mortality due to cardiovascular event x6 after childhood cancer 2 nd cause of late toxicity Cumulative rate of death 4122 survivors after 5 y Treated between 1942-1986 Before age 15 France and U.K. 9 28 mars 2017 EFEC - Clinique de Suivi à Long Terme en Oncologie Pédiatrique Tukenova, JCO, 2010

Cumulative rates at age 45 y Main cardiotoxicities after cancer treatment in childhood and adolescence Ischemia 5.3% vs. 0.9% Clinical cardiac failure 4.8% vs. 0.3% Valvular disease 1.5% vs. 0.1% Arythmia 1.3% vs. 0.4% 10.724 survivors more than 5 y after cancer treatment before 21 y in USA and Canada between 1970 and 1986 vs. 3159 brothers and sisters 12 may 2018 10 Armstrong, JCO, 2013

Congestive heart failure Role of treatment Mulrooney, BMJ, 2009 28 mars 2017

6039 patients treated for Hodgkin in LYSA/EORTC trials between 1964 and 2004 Median age : 30.y Median follow-up 9 y Life situation questionnaire 1238 cardiac events in 703 patients congestive heart disease congestive heart failure arythmia valvular disease 12 may 2018 Maralda, Lancet Oncol 2017 12 Van Nimwegen, JCO, 2015

25/05/2018 13 Long term

Management of treatment-induced cardiotoxicity Pretreatment assessment, Risk reduction, Surveillance and early treatment of cardiotoxicity during therapy, Post-treatment surveillance 25/05/2018 14

For whom? Surveillance for cardiotoxicity How? For patients treated with anthracyclins or cardiac irradiation Cardiac Tripplex U/S Irradiation de l aire cardiaque (dose max) < 20 Gy 20 Gy Dose cumulée d anthracyclines < 300 mg/m² / 5 ans / 3 ans 300 mg/m² / 3 ans / an Complications cardiaques à long terme 15 28 mars 2017 EFEC - Clinique de Suivi à Long Terme en Oncologie Pédiatrique

Role of early treatment with Enalapril 200 pts with LVEF < 45% after anthacycline treatment Treatment with enalapril and whenever possible carvedilol as soon as decrease of LVEF was detected 42% of patients were responders and had a decrease risk of cardiac events Cardinale 2010 25/05/2018 16 Long term

Stroke after irradiation of Willis circle arteries 3172 adults treated for a tumor before age 16 between 1942 and 1985 in France (FCCSS) ; median follow- up 26 y 54 patients with a stroke > 38 ischémic > 16 hemorragic > 1 both Cumulative incidence at age 50 = 6.8% (SIR = 6.9) Among 442 patients treated for a brain tumor 26 stroke Cumulative incidence at age 50 = 26.7% 17 Fayech, 2018

Irradiation of Willis circle arteries: a major risk factor Fayech, 2018 18 EFEC - Clinique de Suivi à Long Terme en Oncologie Pédiatrique

Stroke after Hodgkin lymphoma 2251 HL treated before age 51 between 1965 and 1995 Median follow-up 17.8 y 96 cerebrovascular diseases (55 strokes, 31 TIA, 10 both) Carotid 76% Vertebro-basilar 13% Both 7% Median age at stroke 51 y Outcome 9 died 2 svere symptoms 29 mild symptoms 48 complete recovery Radiation to the neck and mediastinum was an independent risk factor (HR = 2.5, 95%CI1.1-5.6) vs without radiotherapy De Bruyne, JNCI, 2009 25/05/2018 19 Long term

PREVENTION of CARDIOVASCULAR COMPLICATIONS AVOID RISK FACTORS Tobacco Overweight Hypercholesterolemia Diabetes Hypertension PHYSICAL ACTIVITY 20 28 mars 2017 EFEC - Clinique de Suivi à Long Terme en Oncologie Pédiatrique

Suggested follow-up For all patients with cerebral radiotherapy Brain MRI angiography every 5 years Irradiation cervical > 20 Gy : Ultrasonography of carotid vessels every 3-5 years 12 mai 2018 21

Effects of chemo: Antimetabolites and Topo-inhibitors 1. Antimetabolites: Methotrexate, mercaptopurine, cytarabine gemcitabine 1. Topo-inhibitors: etoposide, irinotecan, topotecan 2. Anticancer Antibiotics: bleomycin Osteopenia (High-dose methotrexate) Secondary 11q23 AML (Etoposide>2 g/m 2, 5-10% probability) Lung injury, pulmonary fibrosis, respiratory failure (Bleomycin >300-360 IU, <2% of adolescents) 25/05/2018 22 Pentheroudakis G and Pavlidis N Cancer Treat Rev 2007

Effects of chemo: steroids Hyperglycemia insuline resistance diabetes Hypertension Skin changes, hypertrichosis Myopathy, muscular atrophy Immunosuppression, Osteopenia, osteoporosis, bone necrosis (aseptal femoral head necrosis) Mood disturbances (agitation, depression, anxiety) 25/05/2018 23 Pentheroudakis G and Pavlidis N Cancer Treat Rev 2007

Effects of treatment: Osteopenia Multifactorial, may lead to clinically significant osteoporosis in adult life: Irradiation Chemotherapy-associated hypogonadism Pituitary dysfunction (Cranial irradiation) Hypothyroidism Steroid-induced bone resorption Renal calciuresis and vitamin D deficiency Poor diet and nutrition 25/05/2018 24 Bhatia S et al. JCO 2003

Effects from irradiation: Cranial/Neck/Chest Rx Reduced intellectual capacity-cognition is rare Subclinical verbal, non-verbal, visual-spatial and attentionconcentration deficits Neuroendocrine dysfunction (GH, GnRH, TSH, ACTH low. Prolactin high) Hypothyroidism Cardiopulmonary disease Lung/breast/thyroid cancer 25/05/2018 25 Gurney JG et al. Cancer 2003, Bhatia S et al. JCO 2003, Travis et al. JNCI 2005

Effects from irradiation: Abdomino-pelvic Rx Chronic enteritis Chronic malnutrition Intestinal fibrosis (5%) Tubular and glomerular dysfunction Hypertension (8%) Renal impairment (11%) Calciuresis-osteopenia Bladder fibrosis (rare) Gastric/Colorectal/Pancreatic/Bladder cancer 25/05/2018 26 Gurney JG et al. Cancer 2003, Bhatia S et al. JCO 2003, Travis et al. JNCI 2005

Take home messages Surgery, chemotherapy and irradiation can be associated with substantial toxicity from many target organs, depending on the timing, intensity and combination of regimens These toxicities are of particular concern for AYA because of their young age and very long life expectancy Care of AYA with cancer should be always directed in maximizing efficacy and cure potential and at the same time minimizing short and long term toxicities that can significantly impair young patients quality of life 25/05/2018 27

Thank you for your attention! 25/05/2018 28